What an honor and joy to be able to present on Tuesday and partner with cancer and health industry leaders at HLTH to address unmet needs and work toward improving equitable access to important innovations such as multi-cancer early detection testing. I met with, and listened to, so many healthcare trailblazers these past few days at #HLTH2022, and I am personally more hopeful than ever for the progress that the healthcare industry is continuing to make toward helping patients across the entire disease landscape and throughout the world.
Jeffrey Venstrom, M.D.’s Post
More Relevant Posts
-
Another important milestone for the MCED and cancer screening field, as we advance toward broader access and availability. We are excited to announce First Participant In for REACH! A huge thanks to the #GRAIL team, and our CHN partner Patrick McGill, MD MBA and many others… an unprecedented study! Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH) is a three-year Galleri-Medicare study to evaluate the impacts of multi-cancer early detection (MCED) testing for up to 50,000 Medicare beneficiaries. Now, GRAIL has enrolled its first participant in the study with Community Health Network, an integrated healthcare system in Indiana. This study’s focus on the Medicare population allows us to work with participants from racial and ethnic minorities and seniors from historically underserved communities. Cancer risk increases with age, and more than half of all cancer diagnoses are among Medicare beneficiaries, so we're hopeful this study will continue to reveal MCED testing's potential in cancer screening, especially for populations most in need. Stay tuned as we activate more sites and provide study updates… Learn more:
Today we’re announcing the first participant enrolled in our Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH) Galleri-Medicare study at Community Health Network. We’re evaluating the clinical impact of our multi-cancer early detection (MCED) test in the Medicare population, including racial and ethnic minorities and seniors from historically under-served communities. The three-year, multi-center study will evaluate and compare up to 50,000 Medicare beneficiaries who have received usual care plus an annual MCED test, in addition to recommended cancer screenings, with others who will not receive an annual MCED test. Medicare will cover the costs of MCED testing and routine items and services for study participants. With more than half of all cancer diagnoses among seniors, our commitment at GRAIL is to provide broad, equitable MCED test access to groups that are at the highest risk and underrepresented in clinical research – including the Medicare population. Read more about the news: https://bit.ly/3Wsdeci
To view or add a comment, sign in
-
-
An important update on our clinical trial progress; I’m particularly proud of the diversity and US / UK representation of participants enrolled in our recent studies; huge thanks to Eric Fung, MD, PhD, Margaret M., Sir Harpal Kumar and both broader UK and US teams who made this possible. Stay tuned for results.. it’s an exciting time for #GRAIL and the #MCED field!
Clinical trials update: We’ve completed planned enrollment for the PATHFINDER 2 study and the third and final round of study visits for the NHS-Galleri trial. Both studies successfully enrolled a diverse population, with participants representing various socio-economic, ethnic, gender and age groups. Learn more: https://bit.ly/4bDJZHW
To view or add a comment, sign in
-
-
We are excited to see these new ctDNA data published, with Samsung Medical Center, AstraZeneca, Darren Hodgson, et al; check it out! This study represents an important contribution to future clinical applications of methylation-based cell-free DNA assays. It provides: ➡️ Additional validation of how circulating tumor DNA (ctDNA) shedding correlates with PET avidity and tumor volume ➡️ Prognostic insights among a large early stage lung population ➡️ New insights on how ctDNA detection correlated with higher PD-L1 expression in tumors The findings support the possible integration of ctDNA testing into routine diagnostic workflows in early-stage non-small cell #LungCancer (NSCLC). This testing could be particularly useful in identifying high-risk patients who might benefit from innovative treatments. Stay tuned for more, and check out the the full study:
To view or add a comment, sign in
-
With #ASCO24 wrapping up, I wanted to share a few GRAIL highlights from this year’s congress: ➡️ We showed the potential of adding multi-cancer early detection (MCED) testing to standard-of-care screening for finding cancer recurrence and new primary cancers among cancer survivors ➡️ We also shared data showcasing how adding MCED testing may increase diagnostic efficiency and reduce the time to cancer diagnosis among Medicare patients. Beyond the expansive exchange of information, every year ASCO provides a valuable opportunity to connect with colleagues across the industry on our shared goal to fight cancer. I’m proud to be part of this team, and looking forward to seeing what we accomplish together next.
To view or add a comment, sign in
-
-
#AI in medicine is a hot topic! Thanks to Stand Up To Cancer, Julian Adams, Margaret Foti and exceptional moderator Peter Sorger for an insightful AI innovation summit; it was an honor to present! The impact of AI/ML in the diagnostic field is decades old, starting in radiology and extending to high dimensional NGS diagnostic data for cancer and many other diseases… it’s great to see new Gen AI interest catalyzing greater trust and acceptance of this true transformation in medicine! Kudos to Christina Curtis on presenting new data about the potential role of host ‘Germline Epitope Burden’ predicting cancer risk; it was fun to hear about the challenges and early insights of leveraging real world EHR data for pancreatic cancer risk prediction by Chris Sander and the rising star Adam Yala impressed us with new AI applications for breast and lung cancer screening. I love to see math and science integrated for patient impact… the future is bright!
Today, #StandUpToCancer President & CEO Dr. Julian Adams and several SU2C scientists and researchers took part in the #SU2CAIInnovationSummit! 💡 This event brought together experts in clinical data sciences and early detection diagnostics to understand the significant promise for early detection and improved patient outcomes using #AI. For more updates on our research and funding, follow @SU2CScience on X and visit https://lnkd.in/gt7shUS!
To view or add a comment, sign in
-
-
Kudos to Jordan Karlitz MD, FACG, AGAF, Eric Klein, and coauthors for this new case series describing real-world implementation of multi-cancer early detection! These early cancers detected by the Galleri blood test are challenging to detect early and are not covered by current USPSTF screening guidelines. Read the report: https://lnkd.in/euu__Fwr
A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening - npj Precision Oncology
nature.com
To view or add a comment, sign in
-
We are hiring a Head of Product Safety! Come join the team!
Senior Recruiter & Talent Sourcing Specialist | Clinical Labs, Commercial, Software Engineering, Lab Operations
GRAIL is looking for their next Senior Director for Medical Device or IVD Safety! A few things to note about the role: 👉 Can be located in the San Francisco Bay Area 👉 5 years within medical device safety or patient safety, 15+ years of total clinical experience 👉 MD required 👉 Board-certified (nice to have) 👉 Is NOT a pharmacovigilence role, GRAIL's Galleri Test is a one-time simple blood draw (test) for patients and will not have an ongoing assessment needed. Let me know if you know anyone interested! Here's the role:
GRAIL - Senior Director, Head of Product Safety # 3501
jobs.lever.co
To view or add a comment, sign in
-
Don’t miss Christina Clarke Dur, PhD, MPH Elizabeth O'Donnell, MD, DipABLM, Jeff Allen, Wendy Rubinstein, MD, PhD and esteemed colleagues tomorrow at #aacr2024 discuss and debate the important topic of risk assessment for cancer screening. Here updates on the latest research and different implementation experience for #mced and single cancer screening approaches.
Stay classy San Diego! Looking forward to this and other important discussions at the big American Association of Cancer Research meeting this weekend. This panel, sponsored by BLOODPAC addresses particularly interesting questions for a world with both single-cancer and multi-cancer early detection (MCED) tests: how should we be talking about patients deemed "high-risk" for one cancer type (think, someone with familial polyposis syndrome for colorectal cancer or a heavy smoker for lung cancer) in the context of MCED tests which screen simultaneously for multiple cancer types? Preview: we need a LOT more data about the absolute, age-specific incidence of *all cancers combined* in populations defined by germline mutations/PRS and important risk factors like smoking, BMI, family history, and environmental exposures.
To view or add a comment, sign in
-
Academic Publishing
1yImportant effort!